– Studies have demonstrated several benefits of Empagliflozin, including effectively improving glycemic control, support weight-loss, and reduce cardiovascular-  renal risks in patients with type 2 diabetes mellitus (T2DM). ^1,2,3 Empagliflozin has also demonstrated benefits in heart failure (HF) patients by lowering the cardiovascular (CV) death or hospitalization for HF ^4,5

Bengaluru, March 12, 2025:  Glenmark Pharmaceuticals Ltd. (Glenmark) a research-led, global pharmaceutical company has launched Empagliflozin, a widely recognized SGLT2 inhibitor, in India. The drug has been introduced under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)—Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg).

These medications are designed to improve glycemic control in adults with T2DM while also reducing cardiovascular outcomes in T2DM patients with CV risk. ¹

Empagliflozin is a globally established treatment for HF, T2DM and T2DM with established cardiovascular disease (CVD), offering multiple benefits like cardiovascular and renal safety ⁶. The EMPA-REG clinical trial demonstrated a 14% reduction in major cardiovascular events, positioning Empagliflozin as a significant advancement in T2DM patients with high CV risks.¹

In addition to cardiovascular benefits, studies have highlighted the effectiveness of Empagliflozin and its combinations. A 24-week study found that a twice daily combination of Empagliflozin (12.5 mg) and Metformin (500/1000 mg) helped people with T2DM lower their blood sugar levels (HbA1c by 1.9% to 2.1%), lose weight (3 to 3.8 kg), and reduce fasting blood sugar (by 43.2 to 50.4 mg/dL), with all results being highly significant.² Another 24-week study showed that Empagliflozin (10/25 mg) with Linagliptin (5 mg) helped patients lower their HbA1c (by 1.24%), lose weight (by 2 to 2.7 kg), and reduce fasting blood sugar (by 28.21 to 29.55 mg/dL), proving more effective than either medicine alone.³

Commenting on the launch, Alok Malik, President and Head of India Formulations Business, Glenmark Pharmaceuticals Ltd., said, “ Glenmark has a strong legacy of introducing innovative and accessible treatments for Cardiometabolic care in India. The launch of Glempa range reinforces this commitment by providing a comprehensive and affordable solution that empowers healthcare professionals and patients to manage T2DM with established CVD more effectively.”

Glenmark’s Glempa range is designed to cater to diverse patient needs by offering three treatment options that enhance treatment flexibility and effectiveness. Glempa (Empagliflozin 10mg/25mg) serves as a standalone SGLT2 inhibitor to improve glycaemic control while reducing cardiovascular risks. Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) is a dual-action therapy combining an SGLT2 inhibitor with a DPP4 inhibitor for more effective management of T2DM with cardio renal risks. ^1,7 Meanwhile, Glempa M (Empagliflozin 12.5 mg + Metformin 500/1000 mg) combines the benefits of SGLT2 inhibition with the proven efficacy of Metformin, making it an optimal choice for patients needing stronger glycemic control.

With Cardiovascular diseases and diabetes cases on the rise, Glenmark’s Glempa range aims to provide affordable, high-quality treatment options, improving health outcomes for millions of patients across India

The post Glenmark Pharma Expands Cardiometabolic Portfolio with the Launch of Empagliflozin and its Fixed-Drug Combinations in India  appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.